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ضمور عضلي شوكي قطعي متموضع يف األطراف السفلى
أول حالة تسجل يف عمان
رو�سان كول، اآمنة الفطي�سية، خالد الذهلي، زاندر بروير، باترك �سكوت
abstract: Spinal muscular atrophy (SMA) is a genetic lower motor neuron disease. It usually involves all of 
the skeletal muscles innervated by the anterior horn cells of the spinal cord. In rare cases, there is also localised 
involvement of the spinal cord. We report a 10-year-old boy who presented to the Sultan Qaboos University Hospital, 
Muscat, Oman, in 2015 with muscle weakness restricted to the lower limbs. The presence of a homozygous deletion 
within the survival of motor neuron 1 gene confirmed the diagnosis of SMA. To the best of the authors’ knowledge, 
this is the first report of an Omani patient with segmental SMA involving only the lower limbs. Treatment for this rare 
and relatively benign form of SMA is symptomatic and includes physiotherapy.
Keywords: Spinal Muscular Atrophies of Childhood; Spinal Muscular Atrophy, Segmental; Muscle Weakness; 
Pes Cavus; Case Report; Oman.
امللخ�ص: يعد ال�سمور الع�سلي ال�سوكي القطعي مر�سا وراثيا بالع�سبون احلركي ال�سفلي. وي�سيب املر�ص عادة كل الع�سالت الهيكلية 
التي تع�سبها اخلاليا القرنية االأمامية يف احلبل النخاعي. وتوجد نادرا حاالت اكتناف متمو�سعة يف احلبل النخاعي. ون�سجل هنا حالة 
طفل عمره 10 �سنوات اأدخل مل�ست�سفى جامعة ال�سلطان قابو�ص يف م�سقط، عمان يف عام 2015م ب�سبب �سعف يف الع�سالت حم�سور يف 
االأطراف ال�سفلى. ومت اكت�ساف وجود َخنْب زايجوتي متماثل االأالئل يف داخل جني "بقاء اخلاليا الع�سبية احلركية 1" مما اأكد ت�سخي�ص 
املر�ص على اأنه �سمور ع�سلي �سوكي. ومبلغ علمنا، فهذه هي احلالة االأوىل التي ت�سجل عن مري�ص عماين م�ساب ب�سمور ع�سلي �سوكي 
ع فقط يف االأطراف ال�سفلى. ومت عالج هذه ال�سكل النادر واحلميد ن�سبيا لهذا املر�ص عالجا اأعرا�سيا �سمل العالج الطبيعي. قطعي ُمتمو�سِ
الكلمات املفتاحية: حاالت ال�سمور الع�سلي ال�سوكي عند االأطفال؛ �سمور ع�سلي �سوكي، قطعي؛ �سعف ع�سلي؛ قدم خم�سية؛ ت�سجيل حالة؛ عمان.
Segmental Spinal Muscular Atrophy Localised 
to the Lower Limbs 
First case from Oman
*Roshan Koul,1 Amna Al-Futaisi,1 Khalid Al-Thihli,2 Zandre Bruwer,2 Patrick Scott2
case report
Sultan Qaboos University Med J, Aug 2017, Vol. 17, Iss. 3, pp. e355–357, Epub. 10 Oct 17
Submitted 12 Feb 17
Revision Req. 19 Mar 17; Revision Recd. 18 Apr 17
Accepted 4 May 17 doi: 10.18295/squmj.2017.17.03.018
of SMA are seen every year at the Sultan Qaboos 
University Hospital (SQUH), a tertiary hospital in 
Muscat, Oman. Furthermore, staff at SQUH have 
observed that these children often have an acute 
presentation with a significant progression of weakness 
within days of onset. The majority of children in Oman 
with type I SMA have a homozygous SMN1 gene 
deletion.5 This case report describes a young male 
patient with muscle weakness restricted to the lower 
limbs who was found to have SMA. To the best of 
the authors’ knowledge, this is the first case reported 
from Oman of segmental SMA involving only the 
lower limbs.
Case Report
A 10-year-old boy from Salalah, Oman, presented 
to SQUH in 2015 with muscular weakness confined 
to the lower limbs. The patient had had a delayed 
onset of walking, with his parents noting the lower 
limb weakness only when he first began to walk. At 
Autosomal recessive spinal muscular atrophy (SMA) is a genetic disorder of the lower motor neurons classified into four 
types based on clinical features, age of onset and the 
motor functions affected.1 All four types of SMA 
involve almost all of the skeletal muscles; only the 
muscles innervated by cranial nerves are unaffected, 
excluding those innervated by the hypoglossal nerve.1 
Rarely, there is also localised involvement of the spinal 
cord.2 Type I SMA may present from birth, within 
the first three months of life or after three months 
with patients having a limited ability to sit upright.2,3 
In the majority of cases, the main cause of SMA is a 
homozygous deletion of the survival of motor neuron 1 
(SMN1) gene.4
In Oman, autosomal recessive SMA is the 
most common genetic disease of the lower motor 
neurons.5 In addition, the country has one of the 
highest incidences of this disease worldwide, with 
approximately every one in 6,000 live births affected.5 
According to unreported data, between 6–8 new cases 
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The results of a routine blood work-up were 
normal, although the patient’s serum creatine kinase 
level was slightly elevated at 600 IU/L (normal range: 
50–350 IU/L). Motor and sensory nerve conduction 
studies in the upper limbs were normal. In the lower 
limbs, distal motor latency was mildly delayed in 
all nerves, although sensory nerve conduction was 
normal. The compound muscle action potential was 
reduced overall as compared to the upper limbs. 
Magnetic resonance imaging (MRI) scans of the 
brain, spine and pelvis were normal. Genetic testing 
revealed the homozygous absence of the SMN1 gene, 
confirming the diagnosis of SMA. Unfortunately, the 
family refused to consent to further genetic testing 
of any other family members. At the time of writing, 
the patient was undergoing physiotherapy at a local 
hospital in Oman.
Discussion
This case report describes an Omani boy with 
localised weakness of the lower limbs in whom a 
homozygous SMN1 gene deletion was identified via 
genetic testing. To the best of the authors’ knowledge, 
this type of SMA has not previously been reported 
from this country; moreover, no cases with similar 
presentations of segmental SMA with homozygous 
SMN1 gene deletions are available in the current 
literature. Further genetic testing of the patient’s 
family would have helped to determine the nature 
of inheritance of the condition as well as the carrier 
status; unfortunately, this could not be performed due 
to lack of consent. Patients with autosomal dominant 
distal SMA predominantly involving the upper limbs 
have been previously reported.6
Several variants of SMA not linked to the SMN1 
gene exist, including scapuloperoneal SMA, SMA with 
pontocerebellar hypoplasia, X-linked infantile SMA 
with arthrogryposis, SMA with respiratory distress 
type 1, congenital distal SMA and distal SMA type V/
presentation, he was able to sit up on his own, but 
had difficulty getting up and needed support from 
both hands. After standing, he was able to walk with 
a wide-based waddling gait and foot drop in both feet. 
When walking, he could only move slowly, frequently 
fell and had difficulty climbing stairs. There were no 
complaints regarding his upper limbs. Moreover, 
he had no problems swallowing and there were no 
respiratory symptoms. The patient seemed intelligent 
and had been ranked first in his class at school. His 
parents reported that the weakness in the lower 
limbs had remained the same over the past three 
years. His routine day-to-day activities were not 
affected, although he could not take part in various 
school activities or sports. In terms of family history, 
his parents mentioned that his maternal uncle aged 
32 years old had had a similar presentation in early 
childhood. The patient had four siblings, none of 
whom displayed similar symptoms.
On examination, the patient’s higher mental 
functions and cranial nerves were normal, with no 
tongue fasciculation. The power and tone of the upper 
limbs was normal. The hands had normal grip and 
power and the shoulder girdle muscles had normal 
power, with no winging of the scapula at rest or with 
resistance. The deep tendon reflexes were preserved 
in the upper limbs. The lower limbs looked bulky but 
were weak and the patient had difficulty lifting his 
legs up from the bed. There was no evidence of any 
wasting of the hip girdle or thigh muscles; however, 
there was wasting of the small muscles of both feet. 
The abduction and adduction power at the hips was 
4/5, flexion and extension at the knees was 3/5 and 
dorsiflexion and planter flexion at the ankles was 3/5. 
He had bilateral pes cavus and the long toe flexors and 
extensors were weak with a power of 2/5 [Figure 1]. 
He could walk on his heels but not on his toes and 
Gowers’ sign was positive. Both knee and ankle 
reflexes were absent; however, sensation was normal 
all over the lower limbs.
 
Figure 1: Photographs of a 10-year-old Omani boy with muscle weakness restricted to the lower limbs showing 
(A) bilateral pes cavus and (B) normal hands. The presence of a homozygous deletion within the survival of motor neuron 1
gene confirmed a diagnosis of spinal muscular atrophy.
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Charcot-Marie-Tooth disease type 2d.2 Of these, distal 
SMA with autosomal dominant inheritance involving 
the upper limbs is most common.2 SMA type III with 
SMN1 gene deletion may present in early childhood; 
affected children usually survive till adulthood and 
have a very slow progression of the disease.7,8 With 
regards to the present case, it is possible that the patient 
had a differing phenotype of SMA type III resulting in 
weakness of only the lower limbs.9 As such, there may 
be a progression of weakness over time, eventually 
spreading to the upper limbs. 
There are reports of isolated upper limb or lower 
limb weakness related to anterior horn cell loss.8–10 
Benign juvenile focal amyotrophy of the upper limbs, 
also known as benign focal amyotrophy disorders of 
the limbs or Hirayama disease, was initially reported 
in Japan.10 Schröder et al. reported a case of intrinsic 
motor neuron disease of the lower cervical spinal cord 
in which an MRI revealed localised spinal cord atrophy 
and flattening.11 In another case, Huang et al. reported 
that movement-induced myelopathy could also be an 
underlying mechanism of Hirayama disease; however, 
an autopsy revealed only loss of the anterior horn cells 
without any other changes.12 Hirayama disease is a 
sporadic disorder, although familial cases have been 
reported.6 Similar to cases of upper limb atrophy, 
researchers have also reported amyotrophy restricted 
to the lower limbs, particularly the calf muscles.13 
However, this disease is usually seen in adults, does 
not progress and there is no evidence of sensory loss; 
moreover, there are no upper motor neuron features 
or SMN1 gene deletions in such patients and MRI 
scans of the spine are normal.13
Clinically, segmental SMA resulting in weakness 
of the lower limbs should be differentiated from 
hereditary motor sensory neuropathy, chronic immune- 
mediated demyelinating neuropathy, distal myopathy, 
cauda equina syndrome and myeloradiculopathy. Exam- 
inations of the spine and any sensory abnormalities, 
nerve conduction and genetic tests and, if required, 
muscle/nerve biopsies can aid in confirming a 
diagnosis. To date, physiotherapy remains the main 
mode of treatment for SMA. However, the antisense 
oligonucleotide gene therapy drug nusinersen has 
recently been approved as treatment to prevent the 
progression of the disease.14 
Conclusion
To the best of the authors’ knowledge, this is the first 
case of segmental SMA with SMN1 gene deletion 
reported from Oman. This form of SMA, with 
involvement of only one part of the body, is a rare 
condition. Physiotherapy is currently the mainstay of 
treatment although recent advances in gene therapy 
could be beneficial.
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